Literature DB >> 9739019

Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents.

L Levati1, G Marra, T Lettieri, S D'Atri, P Vernole, L Tentori, P M Lacal, E Pagani, E Bonmassar, J Jiricny, G Graziani.   

Abstract

Cell killing by monofunctional methylating agents is due mainly to the formation of adducts at the O6 position of guanine. These methyl adducts are removed from DNA by the O6-alkylguanine DNA alkyltransferase (OGAT). The mechanism by which O6-methylguanine (O6meG) induces cell death in OGAT-deficient cells requires a functional mismatch repair system (MRS). We have previously reported that depletion of OGAT activity in the human T-cell leukemic urkat line does not sensitize these cells to the cytotoxic and apoptotic effects of the methylating triazene temozolomide (Tentori et al., 1995). We therefore decided to establish whether the tolerance of Jurkat cells to O6meG could be associated with a defect in MRS. The results of mismatch repair complementation studies indicated that Jurkat cells are defective in hMutSalpha, a heterodimer of the hMSH2 and hMSH6 proteins. Cytogenetic analysis of two Jurkat clones revealed a deletion in the short arm of chromosome region 2p15-21, indicating an allelic loss of both hMSH2 and hMSH6 genes. DNA sequencing revealed that exon 13 of the second hMSH2 allele contains a base substitution at codon 711, which changes an arginine to a termination codon (CGA-->TGA). In addition, a (C)8-->(C)7 frameshift mutation in codon 1085-1087 of the hMSH6 gene was also found. Although both hMSH2 and hMSH6 transcripts could be detected in Jurkat clones, the respective polypeptides were absent. Taken together, these data indicate that tolerance of Jurkat cells to methylation damage is linked to a loss of functional hMutSalpha.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9739019

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  5 in total

Review 1.  Constitutional mismatch repair deficiency and childhood leukemia/lymphoma--report on a novel biallelic MSH6 mutation.

Authors:  Tim Ripperger; Carmela Beger; Nils Rahner; Karl W Sykora; Clemens L Bockmeyer; Ulrich Lehmann; Hans H Kreipe; Brigitte Schlegelberger
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

2.  Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.

Authors:  Terzah M Horton; Patrick A Thompson; Stacey L Berg; Peter C Adamson; Ashish M Ingle; M Eileen Dolan; Shannon M Delaney; Madhuri Hedge; Heidi L Weiss; Meng-Fen Wu; Susan M Blaney
Journal:  J Clin Oncol       Date:  2007-11-01       Impact factor: 44.544

3.  MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.

Authors:  Stephen Yip; Jiangyong Miao; Daniel P Cahill; A John Iafrate; Ken Aldape; Catherine L Nutt; David N Louis
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

4.  hMYH and hMTH1 cooperate for survival in mismatch repair defective T-cell acute lymphoblastic leukemia.

Authors:  S Eshtad; Z Mavajian; S G Rudd; T Visnes; J Boström; M Altun; T Helleday
Journal:  Oncogenesis       Date:  2016-12-05       Impact factor: 7.485

5.  Genomic alterations in abnormal neutrophils isolated from adult patients with systemic lupus erythematosus.

Authors:  Namrata Singh; Pamela Traisak; Kayla A Martin; Mariana J Kaplan; Philip L Cohen; Michael F Denny
Journal:  Arthritis Res Ther       Date:  2014-08-08       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.